chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a doctor of pharmacy concerning a patient of unknown age and gender. It was reported that on an unknown date, the patients was vaccinated with a dose of RECOMBIVAX HB (lot # H018691, Exp. date: February 2015), dose and route unspecified) which was exposed to 10 degrees Fahrenheit (F) for 8 hours, which was an excursion that was unsupported by in-house stability data. No concomitant medications were reported. No adverse symptoms were reported. This is one of the three reports from the  same source.  Additional information has been requested.
INADVERTENT DOSE NOT AN ALLERGIC REACTION: Patient came in for a pfizer bivalent booster dose and failed to mention and show us that he had already received a Moderna bivalent booster at another retail pharmacy. He mentioned that he only received vaccine doses with us and we checked his profile to ensure his last dose was with us. He had received his moderna series on 3/5/21, and 4/6/21 with his two regular boosters on 10/22/2021 and 3/30/22. According to his vaccine record he was able to receive the new bivalent booster. Prior to administering I verified on website and saw all the ones listed on his file. Right before administering I asked him again if he had received vaccines elsewhere in the past 2 months or at any other location just to be on the safe side. Again, the patient stated that he thought he had received one end of last year but that did not show on our end and he said he receives all vaccines with us. I administered the vaccine and went into the website again to print him his vaccine record. Upon printing I realized that a moderna bivalent was showing up on 9/29/22 from retail pharmacy in another category of the spreadsheet. I asked patient about this and he said he had forgotten about that one and failed to provide proof of that vaccine when he registered for the vaccine.
Less than 48hrs after the shot I had a big red blotch on my cheek. By Sunday morning I look like I had a bad case of the measles. It is  only on my face and down my chin. I check into what I had eaten or touched but I did nothing out of the ordinary.  My doctor did not what to do.        So on this day of April 30 I still see nothing changed. Please help me.
Fever of 104 degrees, injection site swelling and pain, body aches, and joint pain.  Pt was given ice pack for pain and tylenol for fever.
41 yo healthy woman with history seafood allergy, developed sensation of throat tightness/closing 7 minutes after vaccination. She stated this was similar to sensation she has after exposure to seafood and that these respond to diphenhydramine.  She looked well and had stable vitals. She was observed for10 minutes and did not have worsening symptoms. She was given diphenhydramine 50mg orally and monitored for an additional 60 minutes. She was breathing comfortably, had no dyspnea or wheezing, or swelling of lips, gum, or oropharynx. She reported improved symptoms and was allowed to return to her home. On follow up telephone call 3 hours later, she reported complete resolution of the symptom.
I have genital herpes and have never before had a significant out break, and never one that lasted over 1 week.  The outbreak after shots 1 and 2 lasted 5 months, so far the one after shot 3 has lasted the 4 weeks since the shot.  Both reactions have been bad (7+ lesions) and so far the traditional treatment (valacyclovir) has only had moderate effect.  I have taken 2 courses of the medication and still am not clear.
Pt suffered blisters and redness on the right side of her back wrapping around and under the right breast accompanied with sharp pain. Pt was diagnosed with shingles and nerve pain.; blurry vision; throbbing pain in her eyes; Pt suffered blisters and redness on the right side of her back wrapping around and under the right breast accompanied with sharp pain. Pt was diagnosed with shingles and nerve pain.; Information has been received from a lawyer regarding a case in litigation and refers to a female patient (pt) of an unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 08-FEB-2017, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, dose number, route, anatomical site of vaccination, lot number and expiration date were not provided) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date (reported as shortly after receiving zoster vaccine live (ZOSTAVAX)), the pt suffered blisters and redness on the right side of her back wrapping around and under the right breast accompanied with sharp pain. Pt was diagnosed with shingles (herpes zoster) and nerve pain (neuralgia). Pt also experienced blurry vision (vision blurred) and throbbing pain in her eyes (eye pain) shortly after receiving the vaccine. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccine, pt's symptoms had resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). She also experienced mental and emotional distress due to resulting physical limitations and seriousness of her condition. Pt sustained severe and permanent personal injuries. Pt suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccine, pt had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of neuralgia, herpes zoster, eye pain and vision blurred was not recovered. The reporter assessed that the events were related to zoster vaccine live (ZOSTAVAX).  Neuralgia, herpes zoster, eye pain and vision blurred have been considered disabling events by the reporter.
Around 2pm I blacked out and hit my face on the concrete and went to ER at Hospital.
Swelling at collar bone; lymph node symptoms near collar bone; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (Swelling at collar bone) and LYMPHADENOPATHY (lymph node symptoms near collar bone) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SWELLING (Swelling at collar bone) and LYMPHADENOPATHY (lymph node symptoms near collar bone). At the time of the report, SWELLING (Swelling at collar bone) and LYMPHADENOPATHY (lymph node symptoms near collar bone) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information not provided. List of concomitant medication were not given.   This case was linked to MOD-2021-074208, MOD-2021-074228 (Patient Link).   Reporter did not allow further contact
Dizziness, light-headedness, fatigue, severe nerve pain throughout body, numbing and tingling in the extremities.  Alternating cold and burning sensations throughout body, like acid on the inside.  Weakness in the limbs.    Chest pains, now resolved.  I feel like this has incapacitated me, impairing my ability to function in life.
Headache; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Mar2021 at 08:30 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. The patient's medical history included polycystic ovarian syndrome (PCOS). Concomitant medications included vitamin D (MANUFACTURER UNKNOWN) from an unknown start date for an unknown indication. The patient previously used lavender oil and experienced allergy to it. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Mar2021 at 12:00, the patient experienced headache. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event headache was recovered after the duration of 24 hours.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This spontaneous report as received from a 56 year old female patient, who was also a pharmacist, refers to herself. The patient's concurrent conditions included asthma. She had no drug reactions or allergies. On 26-AU2016, the patient was vaccinated with PNEUMOVAX 23, intramuscularly in the deltoid (dose, lot # and expiry date were not reported). Concomitant therapies included CLIMARA, DULERA, Astelin, NASOCORT, vitamin D and calcium and magnesium supplements. The patient reported that injection hurt like the dickens when it was going in and she had bleeding at the injection site. There was no treatment given for the events. The outcome of the events was reported as not recovered/not resolved (she reported that she continued to have pain at the injection site). The relatedness between the events and PNEUMOVAX 23 was not provided. Additional information is not expected, as reporter did not provide consent to contact physician.
2days following vax pt devel itching & firm erythematous, warm wheal to lt thigh area
Fever, headache, and muscle soreness. Tylenol has helped to reduce symptoms.
a little soreness in arm where the vaccine was injected; This is a spontaneous report from a contactable consumer or other non-healthcare professional. An elderly non pregnant female patient received bnt162b2 (PFIZER-BIONTECH mRNA COVID-19 VACCINE, solution for injection, Lot number was not reported), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Other medications in two weeks were unknown. On 07Feb2021, the patient experienced a little soreness in arm where the vaccine was injected. The outcome of the event was unknown.   Information on the lot/ batch number has been requested.  Follow-up (12May2021): Follow-up attempts completed. No further information expected.
Headache, no appetite, runny nose, dark circles around eyes, extremely dilated pupils, unusually tired, forgetful and mentally unclear, legs hurt and were unstable, erratic body temp, dehydrated, burning light sensitive eyes, rash, dermatitis, hyperactive.
This case was reported by a physician via call center representative and described the occurrence of injection site erythema in a 58-year-old male patient who received Shingrix (batch number 32PE4, expiry date 23rd January 2021) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On an unknown date, less than 3 weeks after receiving Shingrix, the patient experienced injection site erythema, fatigue and injection site pain. On an unknown date, the outcome of the injection site erythema and injection site pain were recovered/resolved and the outcome of the fatigue was recovering/resolving. It was unknown if the reporter considered the injection site erythema, fatigue and injection site pain to be related to Shingrix. Additional details were reported as follows: This case was previously reported to the physician. Approximately 2 to 3 weeks before the dater of reporting, the patient received a dose of Shingrix in left arm. The patient experienced redness and pain at the injection site, which resolved. However, at the time of reporting, the patient was still experiencing fatigue. This case was transferred to medial information. The reporter was unable to provide additional information.
Red , swelling, warmth , pain reaction at injection site.  Size of a baseball.  Still has symptoms 3 days post vaccination
MARCH 13, 2021  - sudden  3 inch x5 inch diagonal band  of redness from  injection site , very hot to touch .  Mild itching MARCh 14,2021- sudden   12"x 3" raised red hive-like rash across left abdomen to center abdomen  also including recent incision area-warm to touch.  Mild itching
Morning after shots, had fever of 102.8 degrees Fahrenheit. That evening arm red, from shoulder to half was down arm, and bruise at injection site. Arm felt hard, rash on chest. Went to ER told her to take Benadryl, thoguht reaction was from DTaP. Next morning redness had spread gave more Benadryl and seemed to be working no more fever.
Cough onset 30" after vaccine positive chest tightness, wheezing, h/a . Essentially resolved by 11/15/16.
very large local rxn;outer aspect of lt arm warm, red tender & itchy 8x10cm;vial cult by provider-negative for bacteria;
had vax on 28APR93 w/in 15 mins devel shrill-high pitched cry which lasted 5 hrs was tx by PMD w/DPH & APAP & ice packs;
The pt received his 1st injection of Twinrix on 1/4/02. On 1/7/02, 3 days post vax, he began to experience muscle aches, body aches, joint pain and rash. On 1/9/02, 5 days post vax, he began to experience fever that ranged from 101F to 103F. He presented for medical attention on 1/12/02. In the physician's office, his temperature was 102.1F.
Soreness at site for 4 days, post vax. Approx. 7 to 10 days, post vax, had episode of flashing light in left eye X several seconds, then experienced dizziness while sitting at a movie theater. Same thing happened 12/1/00, while at luncheon. On 12/3/00, was in the care, when became dizzy; drove to a fire station and saw paramedics. BP was 220/100. Evaluated at hospital and released.
Approx. 3 hours after receiving TDAP pt c/o red, swollen and itchy eyes. Lasted rest of day. Appt here at office was around 9:23 AM. Pt called 9/4/09 to report. No red eyes swelling or itchiness on 9/4/09. Did not have any difficulty breathing. No other meds taken that day.
Itchy, red, raised, warm area about 2-inches in diameter at injection site.
patient is a 19-year-old female presents today complaints of temp of 100.2, myalgias, soreness left deltoid site of injection, wheezing, tingling in her hands. Shortness of Breath headache and sweating fever
No adverse effects reported; since 22-APR-2019, multiple unspecified patients received improperly stored vaccine; This non valid spontaneous report was received from a medical assistant and referred to a multiple unspecified patients of unknown ages and genders. The patients' pertinent medical history, concurrent conditions, drug reactions or allergies were not reported.   On  an unknown dates in 2019 (reported as "since 22-APR-2019"), the multiple unspecified patients were vaccinated with improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ), lot # R027157, expiration date 14-JUL-2020, and lot # R034700, expiration date 16-JUN-2020, (strength, dose, dose number, route, frequency, anatomical location were not reported), for prophylaxis. Other suspect therapies included hepatitis a vaccine, inactivated(VAQTA), lot # S002459, expiration date 15-MAY-2020, (strength, dose, dose number, route, frequency, anatomical location were not reported), for prophylaxis; and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II), lot # R027997, expiration date 01-OCT-2020, (strength, dose, dose number, route, frequency, anatomical location were not reported), for prophylaxis; the measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) was reconstituted with properly stored sterile diluent, lot # R036399, expiration date 20-JUL-2021, and lot # S000977, expiration date 14-SEP-2021.  The temperature/time frame had a duration of 49 hours with a temperature of 9 Celsius Degrees with a highest of 10.4 Celsius Degrees. The vaccines did not experienced any previous temperature excursion. The Digital Data Logger was involved. No adverse effects were reported. It was also reported that the office of the reporter would run a report for the vaccines to determine the patients information.
patient called to report a vaccine related side effect from Prevnar 20: patient is feeling cold, has a headache and achy. patient's voice is also hoarse.
consumer reported that recvd vax during 6th & 9th month period noticed profound hearing loss in pt; 21DEC MD contacted-dx pt has bilateral congenital nerve deafness;
This spontaneous report as received from a 62 year old male consumer with (abnormal) cholesterol refers to himself. The patient had none drug allergies. ON 07-JUN-2013 the patient was vaccinated with ZOSTAVAX (lot # not reported) (subcutaneous in the left arm, 1 time vaccine, strength and total daily dose not reported). Concomitant therapies included LIPITOR. On 07-JUN-2013, he had gotten a symptom similar to a sore throat after getting ZOSTAVAX. He stated it had not gone away after taking 2 round of antibiotics. He also stated that on 07-JUN-2013, his glands were swollen on both side of his throat, to behind the ears. No lab diagnostics studies were performed. He would go back to his physician. At the time of the report, the outcome was unknown. Additional information has been requested.
Irregular menstrual bleeding (spotting) for 48 hours; early onset of period by 2-5 days
Patient started dancing two weeks after receiving their last Covid-19 vaccine; Med Info Agent:  Warm transfer from customer care, case: 00167431 Crosslinked with case: MOD21-092305 Consumer received both Moderna Covid-19 vaccines with no adverse events to report but has a question about why her bill states that she received Sars-Cov-2.  The consumer said son had some side effects and over in a day. The consumer also mentioned her sister got both vaccines and previously had Covid-19 before receiving the vaccines. Covid made her tired and her hair started to fall out. After receiving the vaccines the consumer reports her sister is no longer tired and her hair has grown back. The consumer also stated that one patient who also previously had Covid-19 prior to vaccine administration started dancing two weeks after receiving her second dose of the Covid-19 vaccine. The consumer also states that on news a patient was diagnosed with Covid-19 and did not have  smell or taste. After receiving the Covid-19 vaccine, the consumer reported the patient does not have smell or taste problem any more.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-155334:Same reporter US-MODERNATX, INC.-MOD-2021-155275:Same reporter
Mild hand tremors 1 month after 2nd vaccine/19AUG2022, the tremors has gotten worst; Affecting her ability to work 1 month after 2nd vaccine/Not able to work 6 month after 2nd vaccine; Affecting her ability to  write 1 month after 2nd vaccine; This spontaneous case was reported by a nurse and describes the occurrence of TREMOR (Mild hand tremors 1 month after 2nd vaccine/19AUG2022, the tremors has gotten worst), IMPAIRED WORK ABILITY (Affecting her ability to work 1 month after 2nd vaccine/Not able to work 6 month after 2nd vaccine) and DYSGRAPHIA (Affecting her ability to  write 1 month after 2nd vaccine) in a 55-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     Family history included Tremor (Mother had tremors and Parkinson.) and Parkinson's disease.   In December 2021, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. In January 2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. In February 2022, the patient experienced TREMOR (Mild hand tremors 1 month after 2nd vaccine/19AUG2022, the tremors has gotten worst), IMPAIRED WORK ABILITY (Affecting her ability to work 1 month after 2nd vaccine/Not able to work 6 month after 2nd vaccine) and DYSGRAPHIA (Affecting her ability to  write 1 month after 2nd vaccine). At the time of the report, TREMOR (Mild hand tremors 1 month after 2nd vaccine/19AUG2022, the tremors has gotten worst), IMPAIRED WORK ABILITY (Affecting her ability to work 1 month after 2nd vaccine/Not able to work 6 month after 2nd vaccine) and DYSGRAPHIA (Affecting her ability to  write 1 month after 2nd vaccine) had not resolved.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. After vaccination Patient was unable to work and unable to  write. Patient had an appointment with neurologist. Patient mother had history of tremors and Parkinson. Treatment information was not provided.
Numbness and tingling Left scapular area radiating to left mid axillary line in a linear fashion. Progressed from a pinpoint area to an area 2 inches x 8 inches.
Persistent hives for past 2 weeks on arms, legs, trunk; This is a spontaneous report from a contactable nurse. A 41-year-old non-pregnant female patient received the second dose of BNT162B2 (PFIZER COVID-19 mRNA VACCINE BIONTECH, Lot number: EL9261) via an intramuscular route of administration on the left arm on 12Feb2021 at 15:00 hours as a single dose for COVID-19 immunisation. The patients medical history included allergic to PCN (Penicillin). The patients past drug history included the first dose of BNT162B2 (PFIZER COVID-19 mRNA VACCINE BIONTECH, Lot number: EL3247) via an intramuscular route of administration on the left arm on 22Janb2021 at 15:45 hours as a single dose for COVID-19 immunisation. Since the vaccination, the patient was not tested positive for COVID-19. Concomitant medications included pantoprazole (PROTONIX), cetirizine (ZYRTEC), montelukast sodium (SINGULAIR), fluticasone propionate/salmeterol (ADVAIR) all for unknown indications. On 04Mar2021 the patient experienced hives which were persistent for the past 2 weeks on arms, legs and trunk. No therapeutic measures were taken as a result of the event hives. The clinical outcome of the event hives was not recovered at the time of the report.   No follow-up attempts are possible, No further information is expected.
pt recv vax 3OCT97 & 5OCT97 pt exp severe h/a;
Soreness at the injection site; This is a spontaneous report from a contactable patient.  A 37-year-old female patient (not pregnant) received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number EL3247), via an unknown route, on 27Jan2021 (at 14:15) at single dose on the left arm for COVID-19 immunisation, administered at a clinic. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have a relevant medical history and concomitant medications. No known allergies. On 28Jan2021, the patient developed soreness at the injection site. Post vaccination COVID-19 test was not performed. No treatment was given for the event. The patient recovered from the event on unknown date in 2021.   No follow up attempts are possible. No further information is expected.
This spontaneous report was received from a 63-year-old female patient who refers to herself. The patient's concurrent conditions, medical history, known allergies and concomitant therapies were not reported. In 2014, the patient received a dose of ZOSTAVAX (dose, route of administration, lot# and expiration date were not reported) for "treatment of shingles". In March 2017, the patient experienced shingles. She sought medical attention via office visit and received treatment with cream for the shingles symptoms on an unknown date, in March 2017. The outcome of shingles was not recovered at the time of reporting. The causality was not reported. Additional information is not expected as there was no consent for further contact.